Relative Bioavailability and Food Effect Study With Vericiguat to Characterize the Pediatric Formulation in Adult Healthy Subjects

Trial Profile

Relative Bioavailability and Food Effect Study With Vericiguat to Characterize the Pediatric Formulation in Adult Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Vericiguat (Primary)
  • Indications Chronic heart failure; Coronary artery disease
  • Focus Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 16 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 13 Sep 2017 Planned End Date changed from 7 Sep 2017 to 16 Oct 2017.
    • 30 Jun 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top